Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Povidone iodine nasal spray - IVIEW Therapeutics

Drug Profile

Povidone iodine nasal spray - IVIEW Therapeutics

Alternative Names: Sustained release povidone iodine nasal spray - IVIEW Therapeutics

Latest Information Update: 16 Apr 2020

At a glance

  • Originator IVIEW Therapeutics
  • Class Antiseptics; Antivirals; Disinfectants; Eye disorder therapies; Oxidants; Pyrrolidinones; Skin disorder therapies
  • Mechanism of Action Bacterial protein inhibitors; Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 16 Apr 2020 Chemical structure info added
  • 05 Apr 2020 IVIEW Therapeutics plans clinical trials for COVID-2019 infections
  • 05 Apr 2020 IVIEW therapeutics and Institute for Utah State University plans in-vitro viricidal assay for COVID-19 infections in USA

Development Overview

Introduction

A long-acting povidone iodine (PVP-I) nasal spray is being developed by IVIEW Therapeutics for the prevention and treatment of COVID-19 infections, using an in-situ gel sustain release formulation technology. Povidone iodine, a complex of polyvinylpyrrolidone and iodine, is a powerful disinfectant, effective against viruses, bacteria, fungi, and mold spores with little irritation on skin and low toxicity. Hydrophillic povidone carries iodine to the cell membrane where it is released and complexes with amino acids in bacterial proteins. This causes denaturation of bacterial proteins and also oxidises active groups on bacerial protoplasmic protein leading to bacterial cell death. Microsphere Technology is being used for the development of in-situ gel. Early research development is underway in the US.

Key Development Milestones

Since January 2020, IVIEW Therapeutics and China’s CDE was planning to initiate clinical trials for the prevention and treatment of COVID-19 infections [1] .

Drug Properties & Chemical Synopsis

  • Route of administration Intranasal
  • Formulation Spray
  • Class Antiseptics, Antivirals, Disinfectants, Eye disorder therapies, Oxidants, Pyrrolidinones, Skin disorder therapies
  • Target Bacterial protein; Cell death
  • Mechanism of Action Bacterial protein inhibitors; Cell death stimulants
  • WHO ATC code

    J05A-X (Other antivirals)

  • EPhMRA code

    J5B (Antivirals, excluding anti-HIV products)

  • Chemical name 1-ethenylpyrrolidin-2-one;molecular iodine
  • Molecular formula C6 H9 I2 N O
  • Chemical Structure
  • CAS Registry Number 25655-41-8

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research USA Intranasal / Spray IVIEW Therapeutics 31 Jan 2020
COVID 2019 infections - - Research USA Intranasal / Spray IVIEW Therapeutics 31 Jan 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
IVIEW Therapeutics Originator USA
IVIEW Therapeutics Owner USA
Utah State University Collaborator USA

Development History

Event Date Update Type Comment
16 Apr 2020 Other Chemical structure info added Updated 16 Apr 2020
05 Apr 2020 Trial Update IVIEW Therapeutics plans clinical trials for COVID-2019 infections [1] Updated 16 Apr 2020
05 Apr 2020 Trial Update IVIEW therapeutics and Institute for Utah State University plans in-vitro viricidal assay for COVID-19 infections in USA [1] Updated 09 Apr 2020
31 Jan 2020 Phase Change Early research in COVID-2019 infections (Prevention) in USA (Intranasal) since January 2020 [1] Updated 09 Apr 2020
31 Jan 2020 Phase Change Early research in COVID-2019 infections in USA (Intranasal) since January 2020 [1] Updated 09 Apr 2020

References

  1. iVIEW is developing a safe, non-toxic and long-acting Povidone Iodine nasal spray for the prevention and treatment of COVID-19 infection to curb the COVID-19 spread.

    Media Release
Back to top